SIX patients who were suffering from the acute coronavirus disease 2019 (Covid-19) were cured through the stem cell technology using blood from preserved umbilical cords. The revolutionary method of curing the dreaded virus, which originated in China and has spread worldwide, was announced by The Medical City (TMC) hospital in Pasig City
LAS VEGAS, NV, July 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE Meso Numismatics, Inc.
A majority of patients with relapsed/refractory Hodgkin lymphoma responded to CD30-targeted chimeric antigen receptor (CAR) T-cell therapy, which caused no significant toxicity, a preliminary clinical study showed.
An Emory University-led phase 2 study will evaluate whether the the PI3K-gamma/delta inhibitor duvelisib (Copiktra) is effective at reducing lung inflammation in patients with severe novel coronavirus 2019 (COVID-19), thereby decreasing incidences of mechanical ventilation and death in these patients.1,2 Investigators theorize that the agent will not only work to reduce inflammation and pulmonary edema, but could also potentially decrease duration of viremia and prompt a response from immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies that could in turn respond to SARS-Cov-2 spike proteins.
Analysis of the Global Regenerative Medicine Products Market The presented global Regenerative Medicine Products market report provides reliable and credible insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the global Regenerative Medicine Products market over the forecast period (20XX-20XX). According to the report, the value of the Regenerative Medicine Products market was estimated to reach ~US$ XX in 2019 and attain a market value of ~US$ XX by the end of 2029
DUBLIN, July 30, 2020 /PRNewswire/ -- The "Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The global cell expansion market is projected to reach USD 30.06 billion by 2025 from an estimated USD 14.91 billion in 2020, at a CAGR of 15.1%. The report segments the cell expansion market based on region (Asia Pacific, Europe, North America, and RoW), product (consumables and instruments), cell type (human cells and animal cells), application (regenerative medicine and stem cell research, cancer and cell-based research and other applications), and end user (research institutes, biotechnology and biopharmaceutical companies, cell banks, and other end users).
Be wary of stem cell therapy as a preventative treatment for COVID-19, warns Laertis Ikonomou, a UB expert on stem cell and gene therapies. While stem cell therapy, such as bone marrow transplantation, may be used to treat a limited number of diseases and conditions, there are currently no clinically tested or government-approved cell therapies available for the treatment or prevention of COVID-19, says Ikonomou, associate professor of oral biology in the School of Dental Medicine.
How the thymus shaped immunology The function of the thymus was discovered by Jacques Miller in 1961 and laid a foundation for immunology and modern medicine. Until that time, researchers mistakenly believed the thymus merely represented a remnant of defunct lymph tissue, something of an immune cell graveyard. In a Review, Miller recounts the seminal experiments and conceptual thinking that led to uncovering the critical function of the thymus and provides insights that can be learned from those early days.
TORONTO & MONTREAL--(BUSINESS WIRE)--Regenerative medicine (RM) has the potential to transform healthcare by developing curative therapies for diseases such as heart failure or vision loss. By repairing damaged tissues and organs, this will not only improve patients lives but create economic impact in a market forecasted to reach $5.6B USD by 2025. Several Canadian-made cell therapies will take a major step closer to the clinic thanks to a new collaboration between the Ontario Institute for Regenerative Medicine (OIRM) and the Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine (C3i).
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals.
Recent Comments